Internship

Cyber Security Intern

Posted on 12/20/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

San Diego, CA, USA

Category
Cybersecurity
IT & Security
Requirements
  • Pursuing an undergraduate or graduate degree with an interest in biotechnology
  • Specific degree or field required: cyber security, computer science, or a related technical field
  • Prior experience in the pharmaceutical or biotechnology industry would be an asset but is not required
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes is desirable
  • Good verbal and written communication skills
  • Ability to think creatively and be a team player
  • Offer flexibility with a willingness to work on multiple projects simultaneously
  • Bring to the Company a skill set complementary to its technology and development therapeutics
  • Interest in attending various program events, including social gatherings, career development workshops, and more
  • Ability to commit to a 10-week, full-time summer program
Responsibilities
  • Assist with audits to assess network vulnerabilities and compliance with information security policies
  • Research and test new security tools and technologies to improve threat detection and response
  • Create awareness materials and conduct training to educate employees on cybersecurity best practices
  • Monitor security tools and review logs to identify anomalies or incidents
  • Participate in incident response activities including containment, eradication, and recovery
  • Design automation into current toolsets to enhance response
  • Interacting with all areas within the company
  • Collaborating with a mentor team of cross-functional team members as well as the other interns in the class
  • Completing a special project and presenting the recommendations to senior management upon completion
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY opens a new market for CAH treatment.
  • Positive Phase 2 data for NBI-1117568 boosts Neurocrine's mental health portfolio.
  • Recognition as a top workplace enhances Neurocrine's reputation and employee satisfaction.

What critics are saying

  • Increased competition in CAH treatment may impact CRENESSITY's market share.
  • Potential market saturation for INGREZZA due to similar products.
  • CEO transition could lead to strategic misalignment.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first new CAH treatment in 70 years.
  • INGREZZA SPRINKLE offers a unique formulation for patients with swallowing difficulties.
  • Neurocrine's NBI-1117568 shows promising results for schizophrenia treatment.

Help us improve and share your feedback! Did you find this helpful?